Edgewise Therapeutics (EWTX) Common Equity (2020 - 2026)

Edgewise Therapeutics has disclosed Common Equity across 7 years of filings, most recently posting $493.2 million for Q1 2026.

• Common Equity for Q1 2026 came in at $493.2 million, up 14.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $493.2 million (up 14.77% YoY), and the FY2025 annual result was $522.3 million, up 13.73% from the prior year.
• Common Equity came in at $493.2 million for Q1 2026 at Edgewise Therapeutics, down from $522.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $589.1 million in Q2 2025 to a low of $246.4 million in Q2 2022.
• The 5-year median for Common Equity is $429.7 million (2025), against an average of $414.8 million.
• Across the five-year window, Common Equity soared 68.33% in 2024 and decreased 19.67% in 2025, its largest moves.
• Edgewise Therapeutics' Common Equity stood at $346.7 million in 2022, then dropped by 8.04% to $318.8 million in 2023, then soared by 44.03% to $459.2 million in 2024, then gained by 13.73% to $522.3 million in 2025, then slipped by 5.56% to $493.2 million in 2026.
• The last three Common Equity figures came in at $493.2 million (Q1 2026), $522.3 million (Q4 2025), and $558.6 million (Q3 2025), per Business Quant data.